Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus
Aim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokina...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2023-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2023/4996057 |
| _version_ | 1797366820386111488 |
|---|---|
| author | Yuming Wang Xiaofei Su Wenli Zhang Yunting Zhou Xiao Zhou Wei Yang Huiqin Li Jianhua Ma |
| author_facet | Yuming Wang Xiaofei Su Wenli Zhang Yunting Zhou Xiao Zhou Wei Yang Huiqin Li Jianhua Ma |
| author_sort | Yuming Wang |
| collection | DOAJ |
| description | Aim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokinase activator (GKA), could improve glycemic control and lessen glucose fluctuation in drug-naïve patients with T2DM. Methods. A self-comparative observational study of 25 drug-naïve patients with T2DM (aged 18–75 years and HbA1c of 7.5%–11.0%) treated with dorzagliatin 75 mg twice daily for 52 weeks. Before and after dorzagliatin intervention, the serum levels of hemoglobin A1c (HbA1c), insulin, and C-peptide were measured repeatedly during fasting and after a mixed meal. The continuous glucose monitoring (CGM) device was also used to obtain 24-hour glucose profiles and assess the changes in glycemic variability parameters. Results. After 52 weeks of treatment with dorzagliatin, a numerally greater reduction in HbA1c of 1.03% from the baseline was observed in patients with T2DM, accompanied by significant improvement in insulin resistance and insulin secretion. Moreover, the standard deviation of blood glucose (SDBG) and the mean amplitude of glycemic excursion (MAGE) derived from CGM data were significantly decreased after dorzagliatin therapy. The 24-h glucose variation profile showed that study patients had obviously lower mean glucose levels during the postprandial period from the baseline to week 52, an effect also demonstrated by the significant decrease in the incremental area under glucose concentration versus time curve for 2 h (iAUC0–2 h) after meals. Conclusions. This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM. |
| first_indexed | 2024-03-08T17:10:06Z |
| format | Article |
| id | doaj.art-be3dbb3c5c864607ae54f91b9234b275 |
| institution | Directory Open Access Journal |
| issn | 1687-8345 |
| language | English |
| last_indexed | 2024-03-08T17:10:06Z |
| publishDate | 2023-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj.art-be3dbb3c5c864607ae54f91b9234b2752024-01-04T00:00:07ZengHindawi LimitedInternational Journal of Endocrinology1687-83452023-01-01202310.1155/2023/4996057Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes MellitusYuming Wang0Xiaofei Su1Wenli Zhang2Yunting Zhou3Xiao Zhou4Wei Yang5Huiqin Li6Jianhua Ma7Department of GeriatricsDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyDepartment of PharmacyDepartment of EndocrinologyDepartment of EndocrinologyAim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokinase activator (GKA), could improve glycemic control and lessen glucose fluctuation in drug-naïve patients with T2DM. Methods. A self-comparative observational study of 25 drug-naïve patients with T2DM (aged 18–75 years and HbA1c of 7.5%–11.0%) treated with dorzagliatin 75 mg twice daily for 52 weeks. Before and after dorzagliatin intervention, the serum levels of hemoglobin A1c (HbA1c), insulin, and C-peptide were measured repeatedly during fasting and after a mixed meal. The continuous glucose monitoring (CGM) device was also used to obtain 24-hour glucose profiles and assess the changes in glycemic variability parameters. Results. After 52 weeks of treatment with dorzagliatin, a numerally greater reduction in HbA1c of 1.03% from the baseline was observed in patients with T2DM, accompanied by significant improvement in insulin resistance and insulin secretion. Moreover, the standard deviation of blood glucose (SDBG) and the mean amplitude of glycemic excursion (MAGE) derived from CGM data were significantly decreased after dorzagliatin therapy. The 24-h glucose variation profile showed that study patients had obviously lower mean glucose levels during the postprandial period from the baseline to week 52, an effect also demonstrated by the significant decrease in the incremental area under glucose concentration versus time curve for 2 h (iAUC0–2 h) after meals. Conclusions. This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.http://dx.doi.org/10.1155/2023/4996057 |
| spellingShingle | Yuming Wang Xiaofei Su Wenli Zhang Yunting Zhou Xiao Zhou Wei Yang Huiqin Li Jianhua Ma Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus International Journal of Endocrinology |
| title | Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| title_full | Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| title_short | Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| title_sort | effects of a novel glucokinase activator dorzagliatin on glycemic control and glucose fluctuation in drug naive patients with type 2 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2023/4996057 |
| work_keys_str_mv | AT yumingwang effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT xiaofeisu effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT wenlizhang effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT yuntingzhou effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT xiaozhou effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT weiyang effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT huiqinli effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus AT jianhuama effectsofanovelglucokinaseactivatordorzagliatinonglycemiccontrolandglucosefluctuationindrugnaivepatientswithtype2diabetesmellitus |